$500+ Mn Malaria Opportunity Analysis and Forecasts to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Malaria:
Opportunity Analysis and Forecasts to 2027” report has been
added to ResearchAndMarkets.com’s offering.

“Malaria: Opportunity Analysis and Forecasts to 2027”, provides an
opportunity and forecast assessment on the six pharmaceutical markets
(6M) representing areas with the largest disease burden for malaria. The
countries specifically included in this report are the Democratic
Republic of the Congo (DRC), Ghana, India, Indonesia, Kenya, and
Nigeria. The report covers the market forecast for marketed and
late-stage malaria products.

The malaria market (including the treatment of confirmed incident cases
only, as well as prophylaxis in select at-risk populations) is estimated
to experience moderate growth across the 6M (Democratic Republic of the
Congo, Ghana, Kenya, Nigeria, India, Indonesia) during the forecast
period.

It is estimated that the drug sales across these six countries to be
$57.3M in 2017. Over the 10-year forecast period, the malaria market is
expected to grow at a compound annual growth rate (CAGR) of 24.4%,
surpassing $500M by 2027. This growth would be primarily driven by a
number of interrelated factors, such as the projected uptake of the
malaria vaccines, the uptake of current late-stage pipeline malarial
therapeutics, and the continued use of currently available agents.

Pipeline therapeutics and prophylactics projected to launch during the
forecast period are estimated to have a moderately higher cost compared
to currently available products, but will see use due to the fact that
they are able to partially address unmet needs. The projected increase
in treated malaria cases will also contribute to market growth from
2017-2027.

Key Questions Answered

• How will the malaria market landscape in the 6M (DRC, Ghana, Kenya,
  Nigeria, India, Indonesia) change from 2017-2027?
• What are the most promising late-stage pipeline products for malaria?
• How do the clinical and commercial attributes of late-stage pipeline
  products compare with one another and against existing treatment and
  prevention options?
• What are the remaining unmet needs in the malaria space?
• What drivers and barriers will affect malaria product sales in the 6M?

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies
  through a review of pipeline products and technologies, and by
  identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and
  driving the global malaria market.
• Drive revenues by understanding the key trends, innovative products
  and technologies, market segments, and companies likely to impact the
  malaria market in the future.
• Formulate effective sales and marketing strategies by understanding
  the competitive landscape and by analyzing the performance of various
  competitors.
• Identify emerging players with potentially strong product portfolios
  and create effective counter-strategies to gain a competitive
  advantage.
• Organize your sales and marketing efforts by identifying the market
  categories and segments that present maximum opportunities for
  consolidations, investments, and strategic partnerships.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Malaria: Executive Summary

2.1 Projects Moderate Growth for the Malaria Market from 2017 to 2027

2.2 Biopharmaceutical Industry Effectively Leveraging Public-Private
Partnerships to Advance Novel Malaria Products

2.3 Significant Unmet Needs Will Be Partially Met During the Forecast
Period

2.4 Opportunities Will Exist for New Malaria Therapeutics and
Prophylactics that Fulfill Unmet Needs

2.5 Diverse Pipeline Therapies and First Generation Malaria Vaccines
Positioned to Begin Addressing Unmet Needs

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.1.3 Uncomplicated Malaria

4.1.4 Severe Malaria

4.2 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.3.1 DRC

5.3.2 Ghana

5.3.3 Kenya

5.3.4 Nigeria

5.3.5 India

5.3.6 Indonesia

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for Malaria (20172027)

5.5.1 Confirmed Incident Cases of Malaria

5.5.2 Age-Specific Incident Cases of Malaria

5.5.3 Sex-Specific Incident Cases of Malaria

5.5.4 Confirmed Deaths from Malaria

5.5.5 Confirmed Incident Cases by Plasmodium Species

5.5.6 P. falciparum Cases with K13 Propeller Mutations

5.5.7 Seroprevalence of Plasmodium Infection in Pregnant Women

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment and Prevention Options

6.1 Overview

6.2 Diagnosis and Treatment

6.2.1 Diagnosis

6.2.2 Treatment Guidelines and Leading Prescribed Drugs

6.3 Non-Drug Preventative Interventions

6.4 Drug Therapy Procurement

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Single-Dose Cure to Improve Compliance

7.3 Improved Treatment Options for P. vivax and P. ovale Infections

7.4 Drugs with Novel Mechanisms of Action to Combat Artemisinin
Resistance

7.5 Expanded Options for Difficult-to-Treat Patient Populations

7.6 Options to Block Transmission

8 R&D Strategies

8.1 Overview

8.1.1 Next Generation Therapeutics

8.2 Clinical Trial Design

8.2.1 Controlled Human Malaria Infection (CHMI) Trial Design

8.2.2 Desired Endpoints and Entry Criteria

8.2.3 Combination Therapy Studies

9 Pipeline Assessment

9.1 Overview

9.2 Other Therapeutics and Prophylactics in Development

9.2.1 Therapeutics

9.2.2 Whole Organism Vaccines

9.2.3 Protein-Targeted Vaccines

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Products

10.1.1 Therapeutic Products

10.1.2 Prophylactic Products

10.2 Commercial Benchmark of Key Pipeline Malaria Products

10.2.1 Therapeutic Products

10.2.2 Prophylactic Products

10.3 Competitive Assessment

10.3.1 Therapeutic Products

10.3.2 Prophylactic Products

10.4 Top-Line 10-Year Forecast

11 Appendix

Companies Mentioned

• GlaxoSmithKline (GSK)
• Novartis
• Sanofi
• Takeda
• Sanaria
• Cipla
• Sigma-Tau
• Mepha
• Guilin Pharmaceuticals
• Medicines for Malaria Venture (MMV)

For more information about this report visit https://www.researchandmarkets.com/r/j5k9uz

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Infectious
Diseases Drugs